NCT00905632 - 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2011

Conditions

Hepatitis C, Chronic

Interventions

DRUG

BI 207127 middle dose +SOC

BI 207127 middle dose tid + SOC

DRUG

BI 207127 high dose+SOC

BI 207127 high dose tid +SOC

DRUG

Placebo + SOC

Placebo tid +SOC

DRUG

BI 207127 low dose + SOC

BI 207127 low dose tid + SOC

Trial Locations (18)

1241.7.3307A CHU de Grenoble, Grenoble Cédex 9

1241.7.3303A Hôpital Claude Huriez, Lille

1241.7.3302A Hopital de l'Hotel Dieu, Lyon

1241.7.3301A Hôpital Saint Eloi, Montpellier

1241.7.3305A HOP Archet 2, Nice

1241.7.3306A Hôpital Haut-Lévêque, Pessac

1241.7.3304A HOP de Brabois, Vandœuvre-lès-Nancy

1241.7.49010 Boehringer Ingelheim Investigational Site, Aachen

1241.7.49012 Boehringer Ingelheim Investigational Site, Berlin

1241.7.49004 Boehringer Ingelheim Investigational Site, Essen

1241.7.49011 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1241.7.49001 Boehringer Ingelheim Investigational Site, Hamburg

1241.7.49013 Boehringer Ingelheim Investigational Site, Mainz

1241.7.49009 Boehringer Ingelheim Investigational Site, Regensburg

1241.7.49002 Boehringer Ingelheim Investigational Site, Ulm

1241.7.41003 Boehringer Ingelheim Investigational Site, Basel

1241.7.41004 Boehringer Ingelheim Investigational Site, Lugano

1241.7.41001 Boehringer Ingelheim Investigational Site, Sankt Gallen